NCT01838499

Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa

A Phase IIa Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Assess the Safety, Tolerability and Preliminary Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 224 (actual)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to gain initial evidence for the safety, tolerability and efficacy of MEDI8968 for the treatment of subjects with moderate to severe hidradenitis suppurativa

Conditions

• Hidradenitis Suppurativa

Interventions

Type	Name	Description
BIOLOGICAL	MEDI8968	SC injection at baseline, Week 4 and Week 8
BIOLOGICAL	Saline	SC injection at baseline, Week 4 and Week 8

Timeline

• Start date: 2013-05-01
• Primary completion: 2014-10-01
• Completion: 2014-10-01
• First posted: 2013-04-24
• Last updated: 2016-09-01
• Results posted: 2016-09-01

Locations

27 sites across 1 country: United States